The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Screening of Diabetic Patients for Non-Alcoholic Fatty Liver Disease Based on Liver Indices: A Retrospective Cross-Sectional Study


Affiliations
1 Senior Research Fellow, Kasturba Health Society Medical Research Centre (KHS-MRC), India
2 Physician, KHS-MRC, India
3 Director-Integrative Medicine and Clinical Research, KHS-MRC, India
4 Director-Division of Endocrinology, KHS-MRC, India
     

   Subscribe/Renew Journal


Background and Aims: Non-Alcoholic Fatty Liver Disease (NAFLD) includes a wide spectrum of liver pathophysiology, ranging between relatively benign Nonalcoholic fatty liver to a serious pathology like fibrosis and cirrhosis. NAFLD is commonly associated with Type 2 Diabetes Mellitus (T2DM) and Metabolic Syndrome and may increase the risk for mortality. American Diabetes Association and European Association for the study of Diabetes have recommended screening of all T2DM patients for NAFLD.

Materials and Methods: We did a retrospective analysis of medical records of T2DM patients who attended a diabetes clinic as ambulant patients for 1 year. Out of 215 patients, complete demographic, haemodynamic and biochemical data was available for 46 patients. Simple liver indices like Hepatic Steatosis Index (HSI) and Fibrosis score (FIB-4) were computed.

Results: Presence of steatosis was observed in30 patients based on HSI > 36. Out of these, intermediate risk of advanced fibrosis was observed in 4 patients based on FIB-4 > 1.3.

Conclusion: HSI based screening for steatosis and FIB-4 based screening for fibrosis should be part of liver monitoring in patients with type 2 diabetes mellitus to identify individuals with higher risk for NAFLD.


Keywords

Hepatic Steatosis Index, Fibrosis Score, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.
Subscription Login to verify subscription
User
Notifications
Font Size



  • Screening of Diabetic Patients for Non-Alcoholic Fatty Liver Disease Based on Liver Indices: A Retrospective Cross-Sectional Study

Abstract Views: 205  |  PDF Views: 0

Authors

Anand Shindikar
Senior Research Fellow, Kasturba Health Society Medical Research Centre (KHS-MRC), India
Anushree Mehta
Physician, KHS-MRC, India
Ashwinikumar Raut
Director-Integrative Medicine and Clinical Research, KHS-MRC, India
Rama Vaidya
Director-Division of Endocrinology, KHS-MRC, India

Abstract


Background and Aims: Non-Alcoholic Fatty Liver Disease (NAFLD) includes a wide spectrum of liver pathophysiology, ranging between relatively benign Nonalcoholic fatty liver to a serious pathology like fibrosis and cirrhosis. NAFLD is commonly associated with Type 2 Diabetes Mellitus (T2DM) and Metabolic Syndrome and may increase the risk for mortality. American Diabetes Association and European Association for the study of Diabetes have recommended screening of all T2DM patients for NAFLD.

Materials and Methods: We did a retrospective analysis of medical records of T2DM patients who attended a diabetes clinic as ambulant patients for 1 year. Out of 215 patients, complete demographic, haemodynamic and biochemical data was available for 46 patients. Simple liver indices like Hepatic Steatosis Index (HSI) and Fibrosis score (FIB-4) were computed.

Results: Presence of steatosis was observed in30 patients based on HSI > 36. Out of these, intermediate risk of advanced fibrosis was observed in 4 patients based on FIB-4 > 1.3.

Conclusion: HSI based screening for steatosis and FIB-4 based screening for fibrosis should be part of liver monitoring in patients with type 2 diabetes mellitus to identify individuals with higher risk for NAFLD.


Keywords


Hepatic Steatosis Index, Fibrosis Score, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis.

References